Serox uses photonics and Machine Learning to reduce the time and cost to obtain a clinical diagnosis
Non-invasive, low cost, point-of-care testing is a game changer with respect to accelerating workflow and reducing costs.
Avoid high cost procedures
Our main focus is on avoiding biopsy, cystoscopy, phlebotomy and imaging which can be 100x the cost of an IVD.
Avoid invasive procedures
Phlebotomy, cystoscopy and biopsy come with inherent clinical risk and patient discomfort. We offer the potential to avoid the (up to) 80% of procedures that will be negative.
Avoid unnecessary delays
By reducing unnecessary escalation to critical resource (e.g., biopsy, MRI), that capacity can be used to accelerate workflows for patients that need it.
Serox Ltd
Leveraging the Oxford ecosystem to develop a global product.
Leveraging the Oxford ecosystem to develop a global product.
Our data centric approach allows us to develop models that better serve specific populations, creating a pathway to personalisation for IVD.
Regionalise
Models can be developed to focus on specific groups to accommodate ethnic or regional variations.
Optimise
We will create a market-based mechanism to encourage leading institutions to develop models optimised for the population they serve.
Refine
Models can be developed to accommodate co-morbidities.
Photonics-based disease identification offers the prospects of lower-cost and earlier detection.
Photonics based devices are set to offer enhanced capabilities at lower cost
Cost reductions in critical components coupled with advances in Machine Learning mean that Raman Spectroscopy can now become a low-cost mass-market point-of-care diagnostic.
Stay in touch.
Sign up to our Newsletter.
Serox Ltd
Unit 22, Hanborough Business Park Oxford,
OX29 8LH
© 2024. All rights reserved.